US-based life sciences technology company NanoString Technologies closed its series D funding round yesterday, having raised $20m from a pool of investors including GE Capital, Equity, which acts as the private equity investment unit for energy conglomerate General Electric.
The investment was the first made as part of the GE Healthymagination fund’s commitment, made in September, to spend up to $1bn on cancer research. The round took NanoString’s overall financing to $73.5m since its inception.
Also participating in the round were BioMed…
